A tendency towards worse DFS in the BRCA1 cohort was observed for both patients with hormone receptor-positive (adjusted HR = 0.77, 95% CI 0.58–1.03; Fig. 2b) and negative (adjusted HR = 0.73, 95% CI 0.48–1.13; Fig. 3b) breast cancer (Pinteraction = 0.85; Supplementary Table 5). This evidence concerns the gene BRCA1 and breast carcinoma.